Triple-Negative Breast Carcinoma Clinical Trials

87 clinical trials for Triple-Negative Breast Carcinoma across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer — RECRUITING · NA
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer — RECRUITING · PHASE1
• Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer — RECRUITING · NA
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Access to Genetic Testing in Underserved Patients With Cancer — RECRUITING · NA
• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy — RECRUITING · NA
• Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer — RECRUITING · NA
• Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer — RECRUITING · PHASE2
• Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer — RECRUITING · NA
• Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC — RECRUITING · PHASE2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE3
• STEMVAC in Patients With Early Stage Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden — NOT_YET_RECRUITING · PHASE2
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative — ACTIVE_NOT_RECRUITING · NA
• Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations — TERMINATED · PHASE2
• Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca — ACTIVE_NOT_RECRUITING · PHASE2
• Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery — COMPLETED · PHASE2
• Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer — COMPLETED · PHASE2
• Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer — WITHDRAWN · NA
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer — COMPLETED · PHASE2
• mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian — ACTIVE_NOT_RECRUITING · PHASE1
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• National Cancer Institute "Cancer Moonshot Biobank" — ACTIVE_NOT_RECRUITING
• Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer — COMPLETED · PHASE2
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) — SUSPENDED · NA
• Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer — COMPLETED · PHASE2
• Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer — WITHDRAWN · NA
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy — ACTIVE_NOT_RECRUITING · PHASE1
• Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer — TERMINATED · PHASE2
• Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC — COMPLETED · PHASE2
• Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer — COMPLETED · NA
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies — TERMINATED · PHASE1
• Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer — COMPLETED · PHASE2
• Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• Nipple Aspirate Fluid in Detecting Breast Cancer — COMPLETED · NA
• Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer — COMPLETED · NA
• Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer — WITHDRAWN · PHASE2

Refine this search